Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesNon-ampullary duodenal adenocarcinoma: Factors important for relapse and survival
Journal of Surgical Oncology, 06/23/09
Struck A et al. - In a study to explore treatment outcomes and the impact of radical resection, node-status, and adjuvant therapy, it appears that nodal-status and overall pathological-stage significantly affect prognosis for pts with duodenal adenocarcinoma (DA), while resection-status and adjuvant therapy may not. The role of adjuvant therapy requires prospective trials for elucidation.
Methods- In the past 17 years, 30 pts presented with resectable DA.
- Data on the aforementioned variables were acquired then analyzed for impact on recurrence and survival.
- Overall-survival rates at 1, 2, and 3 yrs were 70.0%, 53.3%, and 33.3% respectively.
- Recurrence-free survival rates at 1, 2, and 3 yrs were 53.3%, 30.0%, and 26.7%.
- Overall-survival rates for pts with node-positive disease at 1, 2, and 3 yrs were 68.8%, 43.8%, 12.5%, and for node-negative 70%, 60%, 60%.
- Recurrence-free survival in node-positive disease at 1, 2, 3 yrs was 50%, 12.5%, 12.5%, and for node negative 50%, 50%, and 40%.
- Median survival from diagnosis was 27.5 mos (0.5-226.7 mos).
- Significant predictors of recurrence and survival were nodal-status and AJCC stage.
- Adjuvant therapy, surgical-type, pathological tumor-stage, and surgical margins were not significant.
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09
Sponsor
Article Search
Sponsor
Sponsor